Epigenetics Market Poised for Robust 18% CAGR Growth Driven by R&D and Therapeutics Demand
The epigenetics market is expected to grow significantly in the coming years, reaching $4.3 billion by 2028 at a CAGR of 18.3% from 2023-2028. The growth is driven by increased investment in epigenetics research and the rising demand for epigenetic-based therapeutics. However, limited applications in toxicology and quality concerns over antibodies may restrain market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
The kits and reagents segment, which includes antibodies, ChiP-seq kits, bisulfite conversion kits, and more, is expected to hold the dominant position in the epigenetics market during the forecast period. This is due to the development of advanced, easy-to-use, and affordable epigenetics kits and reagents.
North America accounted for the largest share of the epigenetics market in 2022 due to the presence of epigenetic manufacturing companies in the region and favorable government and private initiatives supporting the adoption of next-generation sequencing technologies.
Key players operating in the epigenetics market include Thermo Fisher Scientific, Illumina, PacBio, Abcam, Merck KGaA, Active Motif, Bio-Rad Laboratories, Promega Corporation, Zymo Research Corporation, F. Hoffmann-La Roche Ltd, and others. Recent developments in the market include PacBio's acquisition of Apton Biosystems to accelerate next-generation sequencing technology and Illumina's agreement with SomaLogic to introduce proteomic assays on Illumina's NGS platforms.
The epigenetics market is segmented by product and service, method, technique, application, end user, and region. Product and service segments include kits and reagents, enzymes, instruments and accessories, software, and services. Methods include DNA methylation, histone modifications, and other methods like non-coding RNA. Key techniques are next-generation sequencing, PCR/qPCR, mass spectrometry, and sonication. Major applications are in oncology, metabolic diseases, immunology, developmental biology, and more. End users comprise academic and research institutes, biotech and pharmaceutical companies, and hospitals and clinics.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=896
The integration of AI and machine learning in epigenetics presents significant opportunities to transform the understanding of epigenetic mechanisms. However, concerns around antibody quality and limited applications in toxicology remain challenges inhibiting market growth. Overall, increasing R&D investment, demand for epigenetic therapeutics, advancements in biotechnology, and growth in application areas are expected to drive steady expansion of the global epigenetics market through 2028.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com